Pharvaris: Digging Deep For Sufficient Market Size
Seeking Alpha,
Follow Summary Pharvaris is developing a molecule called Deucrictibant to treat acute hereditary angioedema (HAE) and provide…
Follow Summary Pharvaris is developing a molecule called Deucrictibant to treat acute hereditary angioedema (HAE) and provide…
BCX7353 phase 3 trial achieved primary endpoints with statistically significant results.